Ovarian cancer patients with high ca-125 but no symptomsshould antiangiogenic treatments be considered?

Oncology Research

Volumn 9, Issue 2, 1997, Pages 53-54

  Sharma, Amarnath ^a   Bernacki, Ralph J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; CA 125; Human ovarian cancer; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CYCLOHEXANE DERIVATIVE; FUMAGILLOL CHLOROACETYLCARBAMATE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

BLOOD; FEMALE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CYCLOHEXANES; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; SESQUITERPENES;

EID: 0030625561     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kerr, D. J.; Kaye, S. B. Flavone acetic acid -preclinical and clinical activity. Eur. J. Cancer Clin. Oncol. 25:1271-1272; 1989.
2. E.; McCoy, C. L.; Heilbrun, L. K.; Corbett, T. H. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48:4749-41755; 1988.
3. Zwi, L. J.; Baguley, B. C.; Oavin, J. B.; Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J. Natl. Cancer Inst. 81: 1005-1013; 1989.
4. Bibby, M. C.; Double, J. A.; Loadman, P. M.; Duke, C. V. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy. J. Natl. Cancer Inst. 81:216-220; 1989.
5. Smith, G. P.; Calveley, S. B.; Smith, M. J.; Baguley, B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur. J. Cancer Clin. Oncol. 23:1209-1212; 1987.
6. Baguley, B. C.; Calveley, S. B.; Crowe, K. K.; Fray, L. M.; O'Rourke, S. A.; Smith, G. P. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumors in mice. Eur. J. Cancer Clin. Oncol. 25:263-269; 1989.
7. Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Calveley, S. B.; Denny, W. A. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the Colon 38 tumor in vivo. J. Med. Chem. 32:793-799; 1989.
8. Rewcastle, G. W.; Atwell, G. J.; Zhuang, L.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 61. Structureactivity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 34:217-222; 1991.
9. Zwi, L. J.; Baguley, B. C.; Gavin, J. B.; Wilson, W. R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res. 6:79-85; 1994.
10. Ching, L. M.; Joseph, W. R.; Crosier, K. E.; Baguley, B. C. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 54:870-872; 1994.
11. Old, L. J. Tumor necrosis factor (TNF). Science 230:630-632; 1985.
12. Baguley, B. C.; Holdaway, K. M.; Thomsen, L. L.; Zhuang, L.; Zwi, L. J. Inhibition of growth of colon-38 adenocarcinoma by vinblastine and colchicine-evidence for a vascular mechanism. Eur. J. Cancer. 27:482-487; 1991.
13. Hill, S. A.; Lonergan, S. J.; Denekamp, J.; Chaplin, D. J. Vinca alkaloids-anti-vascular effects in a murine tumour. Eur. J. Cancer 29A:1320-1324; 1993.
14. Hill, S. A.; Lonergan, S. J.; Denekamp, J.; Chaplin, D. J. The effect of vinca alkaloids on tumour blood flow. Adv. Exp. Med. Biol. 345:417-422; 1994.
15. Zwi, L. J.; Baguley, B. C.; Gavin, J. B.; Wilson, W. R. Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. Br. J. Cancer 62: 932-934; 1990.
16. Thomsen, L. L.; Ching, L. M.; Zhuang, L.; Gavin, J. B.; Baguley, B. C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 51:7781; 1991.
17. Baguley, B. C.; Cole, G.; Thomsen, L. L.; Zhuang, L. Serotonin involvement in the antitumour and host effects of flavone8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 33:77-81; 1993.
18. Reinhard, J. F.; Moskowitz, M. A.; Sved, A. F.; Fernstrom, J. D. A simple, sensitive and reliable assay for serotonin and 5-HIAA in brain tissue using liquid chromatography with electrochemical detection. Life Sci. 27:905-911; 1980.
19. Anderson, G. M.; Young, J. G.; Batter, D. K. Determination of indoles and catechols in rat brain and pineal using liquid chromatography with fluorometric and amperometric detection. J. Chromatogr. 223:315-320; 1981.
20. Koch, D. D.; Kissinger, P. T. Determination of tryptophan and several of its metabolites in physiological samples by re-versed-phase liquid chromatography with electrochemical detection. J. Chromatogr. 164:441-455; 1979.
21. Ching, L. M.; Joseph, W. R.; Zhuang, L.; Baguley, B. C. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother. Pharmacol. 35:153-160; 1994.
22. Manfred!, J. J.; Horwitz, S. B. Taxol: An antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25:83125; 1984.
23. Philpott, M.; Baguley, B. C.; Ching, L.-M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36:143-148; 1995.
24. Hill, S. A.; Sampson, L. E.; Chaplin, D. J. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int. J. Cancer 63i 119-123; 1995.
25. Ding, A. H.; Porteu, F.; Sanchez, E.; Nathan, C. F. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248:370-372; 1990.
26. Cater, D. B.; Pétrie, A.; Watkinson, D. A. Effect of 5-hydroxytryptamine and cyproheptadine on tumour blood flow. Acta Radiol. Ther. Phys. Biol. 3:109-128; 1965.
27. Jenkins, D. C.; Wilkinson, J.; Lindon, J. C.; Farrant, R. D.; Carpenter, T. A.; Stables, J. N.; Topley, P.; Linstead, D. J.; Holmes, L. S. Anti-tumour effects of 5-hydroxytryptamine (5-HT) are not entirely attributable to its effects on tumour vasculature. Int. J. Radiât. Biol. 60:243-248; 1991.
28. Manda, T.; Nishigaki, F.; Mori, J.; Shimomura, K. Important role of serotonin in the antitumor effects of tumor necrosis factor-alpha in mice. Cancer Res. 48:4250-4255; 1988.
29. Baguley, B. C.; Thomsen, L. L.; Ching, L.-M. Evidence that the 5-hydroxytryptamine antagonist cyproheptadine modulates nitric oxide production in mice in response to flavone acetic acid, vinblastine and other agents. In: Moncada, S.; Marietta, M. A.; Hibbs, J. B., Jr.; Higgs, E. A., eds. Biology of nitric oxide. Part 2. Enzymology, biochemistry and immunology. London: Portland Press; 1992:222-224.